D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 71 Citations 26,295 188 World Ranking 14807 National Ranking 1335

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Chemotherapy

His main research concerns Internal medicine, Colorectal cancer, Surgery, Capecitabine and Fluorouracil. His Internal medicine research integrates issues from Gastroenterology and Oncology. His Oncology research is multidisciplinary, incorporating elements of Clinical endpoint, Ovarian cancer, FOLFOX and Hazard ratio.

His research in Colorectal cancer is mostly focused on Oxaliplatin. Jim Cassidy has included themes like Odds ratio and Clinical trial in his Surgery study. In his study, Metabolite is strongly linked to Pharmacokinetics, which falls under the umbrella field of Chemotherapy.

His most cited work include:

  • Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study (2321 citations)
  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study (1350 citations)
  • Capecitabine as Adjuvant Treatment for Stage III Colon Cancer (941 citations)

What are the main themes of his work throughout his whole career to date?

His scientific interests lie mostly in Internal medicine, Colorectal cancer, Oncology, Chemotherapy and Cancer. His Internal medicine research incorporates themes from Gastroenterology and Surgery. His Colorectal cancer research includes elements of Bevacizumab, Bolus, Survival rate and Hazard ratio.

He focuses mostly in the field of Oncology, narrowing it down to topics relating to Randomized controlled trial and, in certain cases, Physical therapy and Cyclophosphamide. Jim Cassidy combines subjects such as Pharmacokinetics, Pharmacology and Endocrinology with his study of Chemotherapy. His studies in Cancer integrate themes in fields like Cancer research and Pathology.

He most often published in these fields:

  • Internal medicine (49.11%)
  • Colorectal cancer (33.81%)
  • Oncology (32.74%)

What were the highlights of his more recent work (between 2008-2019)?

  • Internal medicine (49.11%)
  • Oncology (32.74%)
  • Colorectal cancer (33.81%)

In recent papers he was focusing on the following fields of study:

Internal medicine, Oncology, Colorectal cancer, Cancer and Chemotherapy are his primary areas of study. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery. His Oncology research includes themes of KRAS, Cetuximab, Irinotecan and First line treatment.

His Colorectal cancer research is multidisciplinary, incorporating perspectives in Adjuvant, Fluorouracil and Hazard ratio. When carried out as part of a general Cancer research project, his work on Metastasis is frequently linked to work in Biomarker discovery, therefore connecting diverse disciplines of study. The Chemotherapy study combines topics in areas such as Radiation therapy, Radiology, Gastrointestinal cancer and Extravasation.

Between 2008 and 2019, his most popular works were:

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study (1350 citations)
  • Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer (301 citations)
  • Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. (220 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

Jim Cassidy mostly deals with Internal medicine, Oncology, Colorectal cancer, Surgery and Oxaliplatin. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. His study in Oncology is interdisciplinary in nature, drawing from both Adjuvant therapy, KRAS, Cetuximab and Irinotecan.

Jim Cassidy has researched Colorectal cancer in several fields, including Fluorouracil and Hazard ratio. He studies Bevacizumab, a branch of Surgery. His Oxaliplatin research incorporates elements of Regimen and Advanced colorectal cancer.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Leonard B. Saltz;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer.
Journal of Clinical Oncology (2008)

3437 Citations

Capecitabine as Adjuvant Treatment for Stage III Colon Cancer

Chris Twelves;Alfred Wong;Marek P. Nowacki;Markus Abt.
The New England Journal of Medicine (2005)

1476 Citations

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Eric Van Cutsem;Chris Twelves;Jim Cassidy;David Allman.
Journal of Clinical Oncology (2001)

1401 Citations

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero.
Journal of Clinical Oncology (2010)

1350 Citations

Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

Martine J. Piccart;Kamma Bertelsen;Keith James;Jim Cassidy.
Journal of the National Cancer Institute (2000)

1183 Citations

Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

Paul A. Vasey;Stan B. Kaye;Rosemary Morrison;Chris Twelves.
Clinical Cancer Research (1999)

1023 Citations

Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

Jim Cassidy;Stephen Clarke;Eduardo Díaz-Rubio;Werner Scheithauer.
Journal of Clinical Oncology (2008)

950 Citations

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.

Johannes Schüller;Jim Cassidy;Etienne Dumont;Brigitte Roos.
Cancer Chemotherapy and Pharmacology (2000)

902 Citations

XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

Jim Cassidy;Josep Tabernero;Chris Twelves;René Brunet.
Journal of Clinical Oncology (2004)

682 Citations

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

J. Cassidy;C. Twelves;E. Van Cutsem;P. Hoff.
Annals of Oncology (2002)

590 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Jim Cassidy

David Cunningham

David Cunningham

Royal Marsden NHS Foundation Trust

Publications: 88

Jos H. Beijnen

Jos H. Beijnen

Antoni van Leeuwenhoek Hospital

Publications: 87

Heinz-Josef Lenz

Heinz-Josef Lenz

University of Southern California

Publications: 80

Josep Tabernero

Josep Tabernero

Vall d´Hebron Institute of Oncology

Publications: 76

Jan H.M. Schellens

Jan H.M. Schellens

Utrecht University

Publications: 76

Axel Grothey

Axel Grothey

University of Tennessee at Knoxville

Publications: 75

Thierry André

Thierry André

Université Paris Cité

Publications: 67

Richard M. Goldberg

Richard M. Goldberg

West Virginia University

Publications: 58

Eric Van Cutsem

Eric Van Cutsem

KU Leuven

Publications: 58

Cornelis J. A. Punt

Cornelis J. A. Punt

University of Amsterdam

Publications: 53

Alfredo Falcone

Alfredo Falcone

University of Pisa

Publications: 52

Karel Ulbrich

Karel Ulbrich

Czech Academy of Sciences

Publications: 51

Volker Heinemann

Volker Heinemann

Ludwig-Maximilians-Universität München

Publications: 50

Marc Peeters

Marc Peeters

University of Antwerp

Publications: 49

Bengt Glimelius

Bengt Glimelius

Uppsala University

Publications: 47

Howard L. McLeod

Howard L. McLeod

Intermountain Healthcare

Publications: 47

Trending Scientists

Nitesh V. Chawla

Nitesh V. Chawla

University of Notre Dame

Chang Wen Chen

Chang Wen Chen

Hong Kong Polytechnic University

Masahiro Yamashita

Masahiro Yamashita

Tohoku University

Per B. Zetterlund

Per B. Zetterlund

University of New South Wales

Shoujun Zhu

Shoujun Zhu

Stanford University

Behnam Pourdeyhimi

Behnam Pourdeyhimi

North Carolina State University

Gerard Cagney

Gerard Cagney

University College Dublin

Philip N. Trathan

Philip N. Trathan

British Antarctic Survey

Daniel L. Rudnick

Daniel L. Rudnick

Scripps Institution of Oceanography

Masatomo Fujiwara

Masatomo Fujiwara

Hokkaido University

Lee J. Martin

Lee J. Martin

Johns Hopkins University School of Medicine

Gregory Krauss

Gregory Krauss

Johns Hopkins University School of Medicine

Scott B. Patten

Scott B. Patten

University of Calgary

Pier Luigi Zinzani

Pier Luigi Zinzani

University of Bologna

Catherine McLoughlin

Catherine McLoughlin

Australian Catholic University

David T. Takeuchi

David T. Takeuchi

University of Washington

Something went wrong. Please try again later.